MAPT and Alzheimer disease: The difference in the cutoff levels among reports might be due to some possible causes such as AD severity of enrolled subjects, subjective assessments on neuropsychological tests, plasma preparation, etc. In this study, the subjects showing plasma Aβ1–42xT-Tau levels higher than 382 pg2/mL2 were referred to subhealth.